Monitoring the safety and effectiveness of Somavert for acromegaly in Korea
Korean Post-marketing Surveillance for Somavert
This study looks at how safe and effective Somavert is for people with acromegaly in Korea by tracking their experiences while using the medication as prescribed by their doctors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Pfizer Industry-sponsored |
| Locations | 1 site (Seoul) |
| Trial ID | NCT05131100 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the safety and effectiveness of Somavert, a treatment for acromegaly, during its post-marketing phase in Korea. It involves collecting data from patients who have been prescribed Somavert according to local guidelines and the judgment of healthcare providers. The study is non-interventional, meaning it does not involve any changes to the patients' treatment plans but rather observes outcomes in routine clinical practice.
Who should consider this trial
Good fit: Ideal candidates include patients in Korea who have been prescribed Somavert for acromegaly as per local regulations.
Not a fit: Patients who are contraindicated for Somavert will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term safety and effectiveness of Somavert for patients with acromegaly.
How similar studies have performed: Other post-marketing surveillance studies have shown success in monitoring drug safety and effectiveness, making this approach well-established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: All patients who have been prescribed as per local label and investigators' judgement under the setting of routine practice in Korea who are eligible. Exclusion Criteria: Patients who are contraindicated for Somavert
Where this trial is running
Seoul
- Pfizer — Seoul, South Korea (Recruiting)
Study contacts
- Study coordinator: Pfizer CT.gov Call Center
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
- Phone: 1-800-718-1021
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.